Sionna Therapeutics, Inc. (NASDAQ: SION)

Sector: Healthcare Industry: Biotechnology CIK: 0002036042
P/B 2.01
P/E -9.16
P/S 0.00
Market Cap 647.28 Mn
ROIC (Qtr) -24.69
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 8.97 Mn
Debt/Equity (Qtr) 0.03

About

Stock Price Chart

Analysis

Pros

  • Healthy cash reserves of 51.79M provide 42.56x coverage of short-term debt 1.22M, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 339.27M provides 37.83x coverage of total debt 8.97M, indicating robust asset backing and low credit risk.
  • Short-term investments of 197.50M provide solid 27.61x coverage of other current liabilities 7.15M, indicating strong liquidity.
  • Long-term investments of 76.67M provide solid 9.89x coverage of long-term debt 7.75M, indicating strategic financial planning.
  • Tangible assets of 339.27M provide robust 47.43x coverage of other current liabilities 7.15M, indicating strong asset backing.

Cons

  • Operating cash flow of (61.45M) barely covers its investment activities of (126.11M), with a coverage ratio of 0.49, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Investment activities of (126.11M) provide weak support for R&D spending of 59.35M, which is -2.12x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Short-term investments of 197.50M significantly exceed cash reserves of 51.79M, which is 3.81x, indicating potentially excessive yield-seeking behavior at the expense of liquidity.
  • The company's operating cash flow of (61.45M) shows concerning coverage of stock compensation expenses of 9.30M, with a -6.60 ratio indicating potential earnings quality issues.
  • Free cash flow of (61.65M) provides weak coverage of capital expenditures of 200000, with a -308.26 ratio suggesting additional external financing needs for growth initiatives.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,349.40 Bn -1,464.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 437.43 Bn 6,381.20 87.97 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 116.09 Bn 31.59 9.90 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 78.10 Bn 17.06 5.48 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.87 Bn 1,282.42 17.40 3.21 Bn
6 ARGX Argenx Se 52.85 Bn 35.08 27,559.65 -
7 BNTC Benitec Biopharma Inc. 41.75 Bn -998.33 0.00 0.00 Bn
8 INSM INSMED Inc 37.80 Bn -31.93 84.56 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 1.81 12.31
EV to Cash from Ops. -10.00 23.25
EV to Debt 68.53 738.44
EV to EBIT -8.70 -9.16
EV to EBITDA -7.60 6.95
EV to Free Cash Flow [EV/FCF] -9.97 21.90
EV to Market Cap 0.95 65.67
EV to Revenue 0.00 227.32
Price to Book Value [P/B] 2.01 22.34
Price to Earnings [P/E] -9.16 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage 0.00 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % -63.93 -27.13
Cash and Equivalents Growth (1y) % 41.08 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % -22.45 -46.93
EBITDA Growth (1y) % -29.91 -1.68
EBIT Growth (1y) % -22.45 -56.45
EBT Growth (1y) % -22.45 -12.70
EPS Growth (1y) % 71.05 -28.31
FCF Growth (1y) % -26.91 -31.90
Gross Profit Growth (1y) % 0.00 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.00 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 5.26 3.85
Current Ratio 25.61 7.27
Debt to Equity Ratio 0.03 0.40
Interest Cover Ratio 0.00 841.00
Times Interest Earned 0.00 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % 0.00 -18,234.31
EBIT Margin % 0.00 -18,580.80
EBT Margin % 0.00 -19,488.74
Gross Margin % 0.00 -7.59
Net Profit Margin % 0.00 -19,439.22